Developing in vivo infection models with MDR pathogens for evaluating compound efficacy

Abstract

A key challenge in drug discovery is predicting the outcome between in vitro activity and clinical efficacy, but in antibiotic discovery, animal models do a credible job of bridging that gap. The ability to utilize the same epidemic, resistant strains and model dosing regimens to those of humans as well as the ability to target specific tissue sites is a powerful tool for designing clinical trials.